Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Withdraws Patent Lawsuit Against Caliper

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — GenMark Diagnostics has withdrawn a lawsuit against Caliper Life Sciences in which it asked a federal court to find that GenMark had not infringed on three patents.

GenMark filed a motion with the US District Court, Northern District of California on Monday, withdrawing its lawsuit filed on Nov. 10, 2010. In its withdrawal, GenMark said the reason for the withdrawal is that Caliper had not "served an answer or motion for summary judgment to date in this matter."

In November, GenMark sued Caliper in a case involving US Patent Number 6,366,924, entitled "Distributed Database for Analytical Instruments;" US Patent Number 6,399,025, entitled "Analtycial System and Method;" and US Patent Number 6,495,104, entitled "Indicator Components for Microfluidic Systems."

The '924 patent pertains to a method for "displaying chromatographic data using a graphical user interface," according to its abstract. The '025 patent covers an analytical or preparatory system employing analytical substrates evaluated in a base unit and methods for performing chemical and biological analyses. The '104 patent pertains to microfluidic devices and systems.

In its complaint, GenMark said that Caliper had communicated through much of 2010 with the company that GenMark was infringing the three patents and "strongly [intimated] that unless a license agreement was reached quickly Caliper would enforce its right under the patent laws. These communications have created an apprehension in GenMark that Caliper intends to sue if GenMark refuses to enter into such a license."

GenMark said in its complaint that it does not believe it has infringed the patents and that it does not believe the patents are valid.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more